Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2016 Aug 18

PMID 27532807

Citations 137

Authors

Yaseen M Arabi

Ali H Hajeer

Thomas Luke

Kanakatte Raviprakash

Hanan Balkhy

Sameera Johani

Abdulaziz Al-Dawood

Saad Al-Qahtani

Awad Al-Omari

Fahad Al-Hameed

Frederick G Hayden

Robert Fowler

Abderrezak Bouchama

Nahoko Shindo

Khalid Al-Khairy

Gail Carson

Yusri Taha

Musharaf Sadat

Mashail Alahmadi

Affiliations

Soon will be listed here.

Abstract

We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trials of convalescent plasma for passive immunotherapy of MERS-CoV infection may be feasible, but such trials would be challenging because of the small pool of potential donors with sufficiently high antibody titers. Alternative strategies to identify convalescent plasma donors with adequate antibody titers should be explored, including the sampling of serum from patients with more severe disease and sampling at earlier points during illness.

Citing Articles

Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19.

Bohonek M, Maca J, Sagan J, rezac D, Fridrich V, Burantova A Virol J. 2024; 21(1):239.

PMID: 39350163 PMC: 11443855. DOI: 10.1186/s12985-024-02475-y.

Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.

Sarfraz A, Sarfraz Z, Bano S, Sarfraz M, Jaan A, Minhas A J Community Hosp Intern Med Perspect. 2024; 14(2):58-66.

PMID: 38966504 PMC: 11221457. DOI: 10.55729/2000-9666.1308.

Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir.

Krismer L, Schoppe H, Rauch S, Bante D, Sprenger B, Naschberger A Npj Viruses. 2024; 2(1):23.

PMID: 38933182 PMC: 11196219. DOI: 10.1038/s44298-024-00028-2.

The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019.

Shi M, Zhang C, Wang F Infect Dis Immun. 2024; 1(1):52-58.

PMID: 38630075 PMC: 8057313. DOI: 10.1097/01.ID9.0000733568.58627.47.

Effectiveness and Controversy of Convalescent Plasma Therapy for Coronavirus Disease 2019 Patients.

Shu Z, Wu P, Qian Q, Zhou L, Du D, Ding M Infect Dis Immun. 2023; 2(1):49-54.

PMID: 37521156 PMC: 8772051. DOI: 10.1097/ID9.0000000000000033.

References

Luke T, Wu H, Zhao J, Channappanavar R, Coleman C, Jiao J . Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016; 8(326):326ra21. DOI: 10.1126/scitranslmed.aaf1061. View

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

Memish Z, Alsahly A, Al Masri M, Heil G, Anderson B, Peiris M . Sparse evidence of MERS-CoV infection among animal workers living in Southern Saudi Arabia during 2012. Influenza Other Respir Viruses. 2014; 9(2):64-7. PMC: 4353318. DOI: 10.1111/irv.12287. View

Zaki A, van Boheemen S, Bestebroer T, Osterhaus A, Fouchier R . Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367(19):1814-20. DOI: 10.1056/NEJMoa1211721. View

Mair-Jenkins J, Saavedra-Campos M, Baillie J, Cleary P, Khaw F, Lim W . The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2014; 211(1):80-90. PMC: 4264590. DOI: 10.1093/infdis/jiu396. View

Callow K, Parry H, Sergeant M, Tyrrell D . The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990; 105(2):435-46. PMC: 2271881. DOI: 10.1017/s0950268800048019. View

Cao W, Liu W, Zhang P, Zhang F, Richardus J . Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007; 357(11):1162-3. DOI: 10.1056/NEJMc070348. View

Alagaili A, Briese T, Mishra N, Kapoor V, Sameroff S, Burbelo P . Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio. 2014; 5(2):e00884-14. PMC: 3940034. DOI: 10.1128/mBio.00884-14. View

Xie L, Liu Y, Fan B, Xiao Y, Tian Q, Chen L . Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Respir Res. 2005; 6:5. PMC: 545044. DOI: 10.1186/1465-9921-6-5. View

10.

Chu D, Poon L, Gomaa M, Shehata M, Perera R, Zeid D . MERS coronaviruses in dromedary camels, Egypt. Emerg Infect Dis. 2014; 20(6):1049-53. PMC: 4036765. DOI: 10.3201/eid2006.140299. View

11.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

12.

Kong L, Zhou B . Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J. 2006; 12(6):489. View

13.

Drosten C, Meyer B, Muller M, Corman V, Al-Masri M, Hossain R . Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014; 371(9):828-35. DOI: 10.1056/NEJMoa1405858. View

14.

Muller M, Meyer B, Corman V, Al-Masri M, Turkestani A, Ritz D . Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015; 15(5):559-64. PMC: 7185864. DOI: 10.1016/S1473-3099(15)70090-3. View

15.

Stockman L, Bellamy R, Garner P . SARS: systematic review of treatment effects. PLoS Med. 2006; 3(9):e343. PMC: 1564166. DOI: 10.1371/journal.pmed.0030343. View

16.

Arabi Y, Balkhy H, Hajeer A, Bouchama A, Hayden F, Al-Omari A . Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015; 4:709. PMC: 4653124. DOI: 10.1186/s40064-015-1490-9. View

17.

Corman V, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M . Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill. 2012; 17(39). DOI: 10.2807/ese.17.39.20285-en. View

18.

Luke T, Kilbane E, Jackson J, Hoffman S . Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med. 2006; 145(8):599-609. DOI: 10.7326/0003-4819-145-8-200610170-00139. View

19.

Hung I, To K, Lee C, Lee K, Yan W, Chan K . Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013; 144(2):464-473. DOI: 10.1378/chest.12-2907. View

20.

. Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect. 2015; 6(4):269-78. PMC: 4588443. DOI: 10.1016/j.phrp.2015.08.006. View